AGENDA

THURSDAY, March 5th

7:00 a.m. – 7:45 a.m.   Breakfast

7:30 a.m. – 7:45 a.m.   Welcoming Remarks and Announcements

7:45 a.m. – 8:00 a.m.   Exam Studying Tips

8:00 a.m. – 10:00 a.m.  Research Design, Statistics, and Evaluating Oncology Literature
    Elyse April MacDonald, Pharm.D., M.S., BCPS
    ACPE Number: 0204-9999-20-912-L04
    Application-based: 2.0 credit hours
    Objectives:
    1. Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
    2. Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
    3. Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
    4. Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

10:00 a.m. – 10:15 a.m.  Break

10:15 a.m. – 11:00 a.m.  Pharmacogenomics in Oncology
    Christine M. Walko, Pharm.D., FCCP, BCOP
    ACPE Number: 0204-9999-20-913-L01
    Knowledge-based: 0.75 credit hours
    Objectives:
    1. Identify appropriate considerations for genetic interpretation in both the germline and somatic settings.
    2. Apply the results from somatic genetic testing into therapeutic recommendations based on prognostic, predictive and patient characteristics.
    3. Recognize the place in therapeutic decision making for companion diagnostic testing.
THURSDAY, March 5th (Continued)

11:00 a.m. – 12:00 p.m.  Prostate Cancer
Steven Ludlow, Pharm.D., BCOP, BCPS
ACPE Number: 0204-9999-20-916-L01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
2. Identify appropriate diagnostic, prognostic and monitoring tests for a patient with prostate cancer.
3. Determine short- and long-term goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
4. Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., factors, prevention, screening).

12:00 p.m. – 1:15 p.m.  Lunch (On own)
Participants are invited to bring their lunch back to the ballroom and participate in an interactive Statistics Practice Session with Dr. MacDonald.

1:15 p.m. – 2:15 p.m.  Melanoma and Non-Melanoma Skin Cancers
Christine M. Walko, Pharm.D., FCCP, BCOP
ACPE Number: 0204-9999-20-915-L01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma and non-melanoma skin cancers.
2. Identify relevant cancer-related molecular biology testing for a patient with melanoma.
3. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.
4. Discuss short- and long-term goals, including post-therapy and survivorship, with the patient with melanoma or non-melanoma skin cancer and his or her caregiver.
5. Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g. risk factors, prevention, and screening).
THURSDAY, March 5th (Continued)

2:15 p.m. – 3:15 p.m.  Gynecologic Malignancies
Tim Peterson, Pharm.D., BCOP
ACPE Number: 0204-9999-20-914-L01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy
2. Compare and contrast the efficacy and toxicity of different routes of drug administration, including IP chemotherapy, in the treatment of ovarian cancer.
3. Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
4. Select relevant information and provide guidance for the public regarding gynecologic malignancy-related issues (e.g., risk factors, prevention and screening) for gynecologic malignancies.
5. Cervical and Endometrial malignancies are covered in the handout only.

3:15 p.m. – 3:30 p.m.  Break

3:30 p.m. – 5:00 p.m.  Chronic Leukemias
Karen M. Fancher, Pharm.D., BCOP
ACPE Number: 0204-9999-20-917-L01
Application-based: 1.5 credit hours
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with chronic leukemia.
3. Determine appropriate pharmacotherapy based on genomic test results in a patient with chronic leukemia.
4. Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
5. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.
FRIDAY, March 6th

7:00 a.m. – 7:45 a.m.  Breakfast

7:30 a.m. – 9:00 a.m.  Multiple Myeloma
Tim Peterson, Pharm.D., BCOP
ACPE Number: 0204-9999-20-918-L01
Application-based: 1.5 credit hours

Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
2. Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression in all oncology patients.
3. Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.

9:00 a.m. – 9:45 a.m.  Adult Sarcoma
Janelle Mann, Pharm.D., BCOP
ACPE Number: 0204-9999-20-919-L01
Knowledge-based: 0.75 credit hours

Objectives:
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
2. Adjust treatment and monitoring plans as needed based on the pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
3. Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

9:45 a.m. – 10:00 a.m.  Break
FRIDAY, March 6th (Continued)

10:00 a.m. – 12:00 p.m.  **Oncology Practice Management**  
Christopher Fausel, Pharm.D., M.H.A., BCOP  
ACPE Number: 0204-9999-20-920-L04  
Application-based: 2 credit hours  
**Objectives:**  
1. Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.  
2. Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.  
3. Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.  
4. Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.  
5. Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

12:00 p.m. – 1:15 p.m.  **Lunch (On Own)**

1:15 p.m. – 2:30 p.m.  **Hematopoietic Stem Cell Transplantation**  
Lauren Ice, Pharm.D., BCPS, BCOP  
ACPE Number: 0204-9999-20-921-L01  
Application-based: 1.25 credit hours  
**Objectives:**  
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT).  
2. Apply appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens, and differentiate between myeloablative, non-myeloablative, and reduced-intensity HSCT conditioning regimens.  
3. Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.  
4. Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HSCT and his or her caregiver.

2:30 p.m. – 2:45 p.m.  **Break**
2020 ACCP/ASHP Oncology Pharmacy Specialty Review and Recertification Course

FRIDAY, March 6th (Continued)

2:45 p.m. – 5:15 p.m. Breast Cancer
Danielle Roman, Pharm.D., BCOP
ACPE Number: 0204-9999-20-922-L01
Application-based: 2.5 credit hours

Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
2. Discuss short- and long-term goals, including post-therapy and survivorship, with the patient with breast cancer and her or his caregiver.
3. Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
4. Identify appropriate diagnostic and prognostic tests related to breast cancer.
5. Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).
SATURDAY, March 7th

7:00 a.m. – 7:45 a.m. Breakfast

7:30 a.m. – 9:00 a.m. Lung Cancer
Janelle Mann, Pharm.D., BCOP
ACPE Number: 0204-9999-20-923-L01
Application-based: 1.5 credit hours
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
2. Identify relevant cancer-related molecular biology testing for a patient with lung cancer.
3. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lung cancer.
4. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
5. Develop a prevention and management strategy for chemotherapy-induced nausea and vomiting for patients with any type of cancer.
6. Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, and screening).

9:00 a.m. – 9:15 a.m. Break

9:15 a.m. – 10:00 a.m. Upper Gastrointestinal and Hepatocellular Carcinomas
Courtney C. Cavalieri, PharmD, BCOP
ACPE Number: 0204-9999-20-924-L01
Application-based: 0.75 credit hours
Objectives:
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
2. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
3. Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.
2020 ACCP/ASHP Oncology Pharmacy Specialty Review and Recertification Course

SATURDAY, March 7th (Continued)

10:00 a.m. – 11:30 a.m.  **Lymphomas**
Karen M. Fancher, Pharm.D., BCOP
ACPE Number: 0204-9999-20-925-L01
Application-based: 1.5 credit hours

*Objectives*
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
2. Assess the prognostic impact of relevant cancer-related molecular biology testing.
3. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

11:30 a.m. – 12:30 p.m.  Lunch (On Own)-Note slightly shorter time today

12:30 p.m. – 1:45 p.m.  **Pediatric Malignancies and Supportive Care**
Jennifer Young, Pharm.D., BCOP
ACPE Number: 0204-9999-20-926-L01
Application-based: 1.25 credit hours

*Objectives:*
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
2. Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
3. Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
4. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a pediatric patient with cancer.
5. Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.
SATURDAY, March 7th (Continued)

1:45 p.m. - 3:00 p.m.  Lower Gastrointestinal and Pancreatic Cancers
Courtney C. Cavalieri, Pharm.D., BCOP
ACPE Number: 0204-9999-20-927-L01
Application-based: 1.25 credit hours

Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
2. Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
3. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer and supportive-care agents for a patient with lower GI or pancreatic cancers.
4. Devise and communicate appropriate plans for preventing, monitoring and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers including chemotherapy-induced diarrhea and dermatologic toxicities from epidermal growth factor receptor inhibitors.
5. Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
6. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

3:00 p.m. – 3:15 p.m.  Break
SATURDAY, March 7th (Continued)

3:15 p.m. – 4:45 p.m.  Adult Acute Leukemias and Myelodysplastic Syndromes
Anthony Perissinotti, Pharm.D., BCOP
ACPE Number: 0204-9999-20-928-L01
Application-based: 1.5 credit hours
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
2. Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
3. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
4. Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results

4:45 p.m.  Closing Remarks
RECORDED ONLY TOPICS
In addition to the programming presented live, there will be three (3 credit hours) additional presentations available in an audio-recorded format prior to the live course. The presentations are as follows:

Bladder, Renal Cell, and Testicular Cancers
Steven Ludlow, Pharm.D., BCOP, BCPS
ACPE Number: 0204-9999-20-929-H01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinoma.
2. Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinoma and his or her caregiver.
3. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.

Cancer-related Infectious Diseases
Jessica Auten, Pharm.D., BCPS, BCOP
ACPE Number: 0204-9999-20-931-H01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during or following cancer treatment based on the current guidelines for treating cancer-related infectious diseases.
2. Discuss short- and long-term treatment goals, including post-therapy, with a patient with a cancer-related infectious disease and his or her caregiver.

Head, Neck and Adult Central Nervous System (CNS) Malignancies
Kelly Fritz, Pharm.D., BCOP
ACPE Number: 0204-9999-20-930-H01
Application-based: 1 credit hour
Objectives:
1. Design an appropriate patient-specific treatment, management and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS) malignancies, or thyroid cancers.
2. Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, and screening).
3. Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.